Additionally, we were able to include all Ontario patients receiving publicly funded biosimilar trastuzumab or Herceptin for neoadjuvant/adjuvant treatment of HER2+ breast cancer through the use of population-based real-world data. Here, ERBB2 is linked to breast carcinoma.